A new study shows that young children diagnosed with pulmonary tuberculosis are at an increased risk of subsequent wheezing, poor lung function, and reduced height and weight later in their childhood.

AMHERST, Mass., April 18, 2023 – In ongoing research aimed at developing more effective treatments for tuberculosis (TB), University of Massachusetts Amherst microbiologists have identified a long-sought gene that plays a critical role in the growth and survival of the TB pathogen.

RESIST-TB released its April 2023 newsletter with the latest updates and research publications on drug-resistant TB.

The World Health Organization (WHO) released a draft document, Global framework to prepare for country introduction of new TB vaccines for adults and adolescents, aiming to guide countries and global stakeholders in preparing for the introduction of new TB vaccines and scale-up in countries.

Advocacy by patients led authorities to reject a patent application for bedaquiline, a drug that shortens treatment and has a higher success rate.

12 Apr 2023 — A new article published today by the Oxford University Press Journal of Intellectual Property Law and Practice shows how fair deals on medical research that ensure equitable access to life-saving medicines can be signed with pharmaceutical companies.

A discovery by researchers at the University of Guelph and the Hospital for Sick Children in Toronto may ultimately lead to new therapies for treating tuberculosis (TB).   

In those talking 3HP for LTBI, female sex, an age from 45 to 54 years, and use of concomitant medications were significantly linked to SDRs and discontinuing treatment.

A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibiotic sensitivity or resistance and its clinical implications. The consensus document provides guidance for the design of therapeutic regimens and the optimization of treatments, and is intended to help clinicians manage tuberculosis patients. The paper, published in The Lancet Infectious Diseases and led by Dr José Domínguez from the Germans Trias i Pujol Research Institute (IGTP), is an update of a similar statement made in 2016. The publication presents a review of the current tools to rapidly identify resistance to drugs used in the treatment of tuberculosis.